The Effect of Physical Therapy Intervention on Motor Performance in Bhutanese Preterm Infants

Sponsor
JDWNRH (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06109350
Collaborator
(none)
28
1
2
14
2

Study Details

Study Description

Brief Summary

The purpose of this randomized controlled trial is to assess if physical therapy intervention works well to improve motor performance in Bhutanese preterm infants.The main question the study aims to answer is:

Will physical therapy intervention improve the motor performance of preterm infants at 3 months of corrected age when compared to the preterm infants receiving standard care of parental education? In this study the motor performance of the preterm infants receiving physical therapy intervention and standard care will be compared.

Condition or Disease Intervention/Treatment Phase
  • Other: Supporting play exploration and early developmental intervention(SPEEDI)
  • Other: Standard care
N/A

Detailed Description

After receiving parental consent, preterm infants meeting the eligibility criteria will be enrolled for the study. 28 preterm infants will be enrolled and followed up from 40 weeks till 3 months of corrected age.

The preterm infants in the intervention group will receive modified supporting play, exploration and early development intervention(SPEEDI) and the standard group will receive standard care. The intervention for both groups will be provided by the physical therapists. The SPEEDI intervention should be carried out by the parent for at least 20mins/day for 5 days in a week. The parent will be asked to bring the infants for monthly follow up.

The motor performance of the preterm infants from this two groups will be assessed at 40 weeks, 1, 2 and 3 months of corrected age. The measurement tool that will be used to assess the preterm infants are Test for Infant Motor Performance(TIMP) and Rapid Neurodevelopment Assessment(RNDA). The assessment will be performed by therapist who will be blinded to the group allocation.

The end point of the study is at 3 months of corrected age.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
28 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Masking Description:
Double blinded with the outcome assessor blinded to the group allocation and the parent of preterm infants will be blinded since they will be scheduled for appointment on the different day. The outcome assessor will not be disclosed with the infants information, such as age , any medical diagnosis and group identification.
Primary Purpose:
Supportive Care
Official Title:
The Effect of Modified Supporting Play, Exploration and Early Development on Motor Performance in Bhutanese Preterm Infants- Randomized Controlled Trial
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supporting play exploration and early development intervention

Preterm infants will receive supporting play exploration and early developmental intervention till 3 months of corrected age.

Other: Supporting play exploration and early developmental intervention(SPEEDI)
SPEEDI will be performed by the parents

Active Comparator: Standard care

Preterm infants will receive standard care mostly including health education till 3 months of corrected age.

Other: Standard care
Standard care will be performed by the parents

Outcome Measures

Primary Outcome Measures

  1. Compare the motor performance using Test for Infant Motor Performance(TIMP) [40 weeks, 1, 2, and 3 months of corrected age]

    TIMP is a validated tool to measure the motor performance from 34 weeks post menstrual age through 4 months corrected age. The 42 items on the test provides comprehensive assessment of head and trunk control and arms and legs movement. The total score of TIMP ranges from 0-142 with higher scores representing better motor outcome and lower score representing motor delay.

Secondary Outcome Measures

  1. Compare the neurodevelopment using Rapid Neurodevelopment Assessment(RNDA) [40 weeks, 1, 2, and 3 months of corrected age]

    RNDA is a validated tool to assess the neurodevelopment from birth to 2 years. It used to assess developmental domains such as primitive reflex, gross motor, fine motor, vision, hearing, speech, cognition and behavior. The assessment can be interpreted into four categories which are no, mild, moderate and severe impairment.

Other Outcome Measures

  1. Compare the compliance of the parents [1, 2, and 3 months]

    Parental compliance will be measured by the ability of the parent to correctly demonstrate the home program activity when they come for follow up visit .

Eligibility Criteria

Criteria

Ages Eligible for Study:
28 Weeks to 34 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Infants born between 28 -34 weeks of gestation

  • Medically stable and off ventilator at the time of discharge from the hospital

  • Parents who consent to come for follow up

Exclusion Criteria:
  • Cortical blindness or retinopathy of prematurity causing blindness

  • Musculoskeletal/congenital abnormalities

  • Brain injuries including intra-ventricular hemorrhage (grade 3 and above), hypoxic ischemic encephalopathy and hydrocephalus

  • Genetic syndrome

  • Family who do not consent

  • Parent with physical and psychological problems

  • Infants with medical devices such as NG tube and gastrostomy

  • Infants who have undergone major surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jigme Dorji Wangchuck National Referral Hospital(JDWNRH) Thimphu Bhutan 11001

Sponsors and Collaborators

  • JDWNRH

Investigators

  • Principal Investigator: Karma Lhaki, JDWNRH

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Karma Lhaki, Deputy Chief Physiotherapist, JDWNRH
ClinicalTrials.gov Identifier:
NCT06109350
Other Study ID Numbers:
  • IRB/Approval/PN/2023/002/564
First Posted:
Oct 31, 2023
Last Update Posted:
Oct 31, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Oct 31, 2023